Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report

BACKGROUND: Nintedanib is a multi-target receptor tyrosine kinase inhibitor. In two recent randomized phase 3 trials (INPULSIS™-1 and -2), it has been shown to slow the disease progression of idiopathic pulmonary fibrosis (IPF) by reducing the decline in the forced vital capacity (FVC). Although the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMC Pulm Med
Huvudupphovsmän: Ikeda, Satoshi, Sekine, Akimasa, Baba, Tomohisa, Yamakawa, Hideaki, Morita, Masato, Kitamura, Hideya, Ogura, Takashi
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2016
Ämnen:
Case Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4778330/
https://ncbi.nlm.nih.gov/pubmed/26940352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-016-0201-9
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk